Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Pontificia Universidad Catolica De Chile maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is distributed among 1 distinct examiner and 1 distinct art unit, reflecting 1 point of prosecution for the university's current filings. The presence of 1 distinct art unit indicates that the current patenting activity is confined to a specific scientific domain rather than being spread across multiple research disciplines.
IVANOVA, SVETLANA M serves as the busiest examiner with 1 pending office action. As this examiner oversees the only active action, the university's current progress in this technology sector is tied to a single examiner's review process. With 1 pending office action in total, the prosecution strategy must be highly tailored to the specific feedback from this examiner, as there are no other pending actions to provide alternative paths for portfolio growth. The university must focus its resources on resolving the 1 pending office action to advance its Biotechnology & Pharmaceuticals interests.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IVANOVA, SVETLANA M | 1 | 50.9% | +51.5% |
| GERIDO, DWAN A | 1 | 58.0% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17420520 | BIOCHEMICAL DIAGNOSTIC TEST FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) | GERIDO, DWAN A | 28d |
| 18576018 | USE OF ESTRETOL AS A TREATMENT FOR ENDOMETRIOSIS | IVANOVA, SVETLANA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17420520 | BIOCHEMICAL DIAGNOSTIC TEST FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) | GERIDO, DWAN A | 28d |
| 18576018 | USE OF ESTRETOL AS A TREATMENT FOR ENDOMETRIOSIS | IVANOVA, SVETLANA M | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18576018 | USE OF ESTRETOL AS A TREATMENT FOR ENDOMETRIOSIS | IVANOVA, SVETLANA M | 1627 | §102§103§112 | Final Rejection | — | Pending | Mar 18, 2024 |
| 17420520 | BIOCHEMICAL DIAGNOSTIC TEST FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) | GERIDO, DWAN A | 1797 | §101§112 | Non-Final OA | 28d | Pending | Jul 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial